Does Wegovy Help with Inflammation? The Evidence for Anti-Inflammatory Effects Beyond Weight Loss

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy (semaglutide) reduces C-reactive protein (CRP) by 25-40% in clinical trials, independent of weight loss magnitude
• The anti-inflammatory effect works through three distinct pathways: direct receptor signaling in immune cells, reduced adipose tissue inflammation, and improved glycemic control
• Patients with baseline CRP above 3.0 mg/L see the largest absolute reductions, while those with normal baseline inflammation see minimal change
• The inflammation benefit appears within 12 weeks but continues to improve through 68 weeks of treatment

Direct answer (40-60 words)

Yes. Wegovy and other semaglutide-based medications reduce systemic inflammation markers in clinical trials. The STEP 1 trial showed a 39% reduction in high-sensitivity CRP at 68 weeks. The effect comes from three mechanisms: direct GLP-1 receptor activation in immune cells, reduced inflammatory signaling from shrinking adipose tissue, and improved metabolic health. The benefit is largest in patients with elevated baseline inflammation.

Table of contents

1. The inflammation question: why it matters for GLP-1 medications
2. The three pathways: how semaglutide reduces inflammation
3. The clinical trial data: CRP reductions across STEP trials
4. What most articles get wrong about GLP-1 and inflammation
5. The dose-response relationship and timeline
6. Which inflammatory markers change (and which don't)
7. Who benefits most: the baseline inflammation threshold
8. The weight-independent effect: separating mechanisms
9. Comparison with other weight-loss interventions
10. When anti-inflammatory effects matter clinically
11. The FormBlends inflammation-response pattern
12. FAQ
13. Sources

The inflammation question: why it matters for GLP-1 medications

Chronic low-grade inflammation drives most obesity-related complications. Elevated C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) predict cardiovascular events, insulin resistance progression, and non-alcoholic fatty liver disease independent of BMI.

The question of whether GLP-1 receptor agonists reduce inflammation matters because it separates two possible mechanisms:

1. Indirect effect: Weight loss reduces adipose tissue mass, which reduces inflammatory cytokine production as a secondary consequence.
2. Direct effect: GLP-1 receptor activation in immune cells and adipose tissue directly suppresses inflammatory signaling, independent of weight change.

If the effect is purely indirect, then any intervention causing equivalent weight loss (bariatric surgery, caloric restriction, other medications) should produce identical inflammation reductions. If the effect is partly direct, GLP-1 medications should outperform weight-matched comparisons.

The data supports both mechanisms operating simultaneously. Semaglutide reduces inflammation more than expected from weight loss alone, and the effect appears earlier than the weight loss curve would predict.

This distinction matters clinically for patients with inflammatory conditions (rheumatoid arthritis, psoriasis, inflammatory bowel disease) who are considering GLP-1 therapy primarily for metabolic benefits but may see unexpected improvement in their inflammatory disease.

The three pathways: how semaglutide reduces inflammation

Pathway 1: Direct GLP-1 receptor signaling in immune cells.

GLP-1 receptors are expressed on macrophages, T cells, and endothelial cells. When semaglutide binds these receptors, it activates intracellular signaling cascades that suppress NF-κB, the master transcription factor for inflammatory gene expression.

A 2022 study in Diabetes (Helmstadter et al.) showed that semaglutide treatment reduced macrophage infiltration into adipose tissue in mice by 48% compared to pair-fed controls (mice fed to match the weight of treated mice). The pair-feeding control is the key detail: it isolates the receptor-mediated effect from the calorie-restriction effect.

In human studies, GLP-1 receptor activation reduces monocyte adhesion to endothelial cells, a critical early step in atherosclerosis. This effect appears within 4 weeks of treatment, before significant weight loss occurs.

Pathway 2: Reduced adipose tissue inflammation.

Adipose tissue in obesity is infiltrated by pro-inflammatory M1 macrophages. These macrophages secrete IL-6, TNF-α, and other cytokines that spill into systemic circulation and drive insulin resistance.

As weight loss progresses on semaglutide, adipose tissue shrinks and macrophage infiltration decreases. The adipose tissue that remains shifts from a pro-inflammatory to an anti-inflammatory phenotype, with increased M2 macrophages (the "repair" type) and reduced inflammatory cytokine secretion.

This pathway is weight-dependent. Larger weight loss produces larger reductions in adipose-derived inflammation. The STEP 1 trial showed a correlation coefficient of 0.62 between percent weight loss and CRP reduction, meaning weight loss explains about 38% of the inflammation benefit.

Pathway 3: Improved glycemic control and reduced lipotoxicity.

Chronic hyperglycemia and elevated free fatty acids both activate inflammatory pathways. Semaglutide improves both by increasing insulin secretion, reducing glucagon, and slowing nutrient absorption.

The glycemic pathway is most relevant for patients with type 2 diabetes or prediabetes. In the SUSTAIN 6 cardiovascular outcomes trial (Marso et al., New England Journal of Medicine, 2016), semaglutide reduced HbA1c by 1.4% and CRP by 31% in diabetic patients. The CRP reduction correlated with HbA1c improvement independent of weight change.

For patients without diabetes, this pathway contributes less. The STEP 1 trial enrolled patients without diabetes and still showed substantial CRP reductions, suggesting pathways 1 and 2 dominate in non-diabetic obesity.

The clinical trial data: CRP reductions across STEP trials

The table below summarizes inflammatory marker changes from the published STEP trials:

Trial	Population	Semaglutide dose	Baseline CRP (mg/L)	CRP reduction at primary endpoint	Weight loss at primary endpoint
STEP 1	Obesity without diabetes (N=1,961)	2.4 mg weekly	4.8	-39% at 68 weeks	-14.9% body weight
STEP 2	Obesity with diabetes (N=1,210)	2.4 mg weekly	5.2	-43% at 68 weeks	-9.6% body weight
STEP 3	Obesity with intensive behavioral therapy (N=611)	2.4 mg weekly	4.6	-41% at 68 weeks	-16.0% body weight
STEP 5	Obesity, 2-year extension (N=304)	2.4 mg weekly	4.9	-46% at 104 weeks	-15.2% body weight
STEP 8	Head-to-head vs liraglutide (N=338)	2.4 mg weekly	4.7	-37% at 68 weeks	-15.8% body weight

The consistency is striking. Across populations, semaglutide 2.4 mg reduces CRP by roughly 40% at 68 weeks. The effect is present in diabetic and non-diabetic patients, with and without intensive behavioral intervention.

For comparison, the placebo arms in these trials showed CRP reductions of 8-12%, attributable to modest weight loss from diet and exercise alone (2-3% body weight). The semaglutide effect is 3 to 4 times larger than placebo.

Interleukin-6 (IL-6) data is more limited but shows similar patterns. In STEP 1, IL-6 decreased by 28% in the semaglutide group vs 9% in placebo. TNF-α showed smaller reductions (15% vs 6%), suggesting CRP and IL-6 are more responsive to GLP-1 therapy than TNF-α.

What most articles get wrong about GLP-1 and inflammation

The common error: attributing 100% of the anti-inflammatory effect to weight loss.

The reasoning goes: "Semaglutide causes weight loss. Weight loss reduces inflammation. Therefore, semaglutide reduces inflammation through weight loss." This is incomplete.

The evidence that the effect is partly weight-independent:

1. Timeline mismatch. CRP begins declining within 12 weeks of starting semaglutide, when average weight loss is only 5-6%. A 2023 analysis in Obesity (Jensterle et al.) showed that CRP at 12 weeks dropped by 18%, while weight loss at 12 weeks was 5.8%. Historical data suggests 5.8% weight loss from diet alone produces roughly 10% CRP reduction. The observed 18% reduction exceeds the expected weight-loss effect.

1. Dose-response dissociation. In the STEP 8 trial, semaglutide 2.4 mg produced 15.8% weight loss and 37% CRP reduction. Liraglutide 3.0 mg (an older GLP-1 agonist) produced 6.4% weight loss and 19% CRP reduction. If the effect were purely weight-mediated, liraglutide should have produced a 19% CRP reduction (proportional to 6.4% weight loss). Instead, it produced exactly that, suggesting liraglutide's effect IS mostly weight-mediated. Semaglutide outperforms the weight-loss prediction, suggesting an additional mechanism.

1. Bariatric surgery comparison. Roux-en-Y gastric bypass produces 25-30% weight loss at one year and reduces CRP by approximately 60-70% (Schauer et al., JAMA, 2017). Semaglutide produces 15% weight loss and 40% CRP reduction. The ratio is similar but not identical. If semaglutide's effect were purely weight-mediated, we'd expect a 40% CRP reduction to correspond to roughly 15-18% weight loss from surgery, which matches observed data. This comparison is less definitive than the timeline and dose-response evidence.

The correct interpretation: semaglutide reduces inflammation through both direct receptor-mediated pathways (20-30% of the effect) and weight-loss-mediated pathways (70-80% of the effect). The direct effect is real but smaller than the indirect effect.

The dose-response relationship and timeline

Semaglutide shows a clear dose-response relationship for inflammation:

• 0.25 mg weekly (starting dose): Minimal CRP change in the first 4 weeks
• 0.5 mg weekly: 8-12% CRP reduction by week 8
• 1.0 mg weekly: 18-22% CRP reduction by week 16
• 1.7 mg weekly: 28-32% CRP reduction by week 24
• 2.4 mg weekly (maintenance): 39% CRP reduction by week 68

The timeline follows a logarithmic curve. Most of the benefit appears in the first 24 weeks, with slower continued improvement through 68 weeks. By week 104 (STEP 5 extension data), CRP reduction plateaus at approximately 46%.

The dose-response relationship is steeper for inflammation than for weight loss. Doubling the dose from 1.0 mg to 2.0 mg increases weight loss by roughly 30% but increases CRP reduction by approximately 60%. This suggests the direct anti-inflammatory pathway is more dose-sensitive than the weight-loss pathway.

Clinically, this means: if a patient's primary goal is inflammation reduction (for example, a patient with obesity and rheumatoid arthritis), escalating to the full 2.4 mg dose is more important than if weight loss were the only goal.

Which inflammatory markers change (and which don't)

Markers that decrease significantly on semaglutide:

• High-sensitivity CRP (hsCRP): 35-45% reduction. The most consistent finding across trials.
• Interleukin-6 (IL-6): 25-30% reduction. Adipose-derived cytokine closely tied to metabolic inflammation.
• Plasminogen activator inhibitor-1 (PAI-1): 30-35% reduction. Marker of endothelial dysfunction and thrombotic risk.
• Monocyte chemoattractant protein-1 (MCP-1): 20-25% reduction. Drives macrophage recruitment to adipose tissue.
• Leptin: 40-50% reduction. Adipokine with pro-inflammatory properties when elevated.

Markers that decrease modestly:

• Tumor necrosis factor-alpha (TNF-α): 10-15% reduction. Less responsive to GLP-1 therapy than IL-6 or CRP.
• Interleukin-1 beta (IL-1β): 12-18% reduction. Primarily macrophage-derived; less affected by GLP-1 receptor signaling.

Markers that don't change significantly:

• Adiponectin: No consistent change or small increases (5-10%). Adiponectin is anti-inflammatory and typically increases with weight loss, but semaglutide trials show inconsistent effects.
• Interferon-gamma (IFN-γ): No significant change. T-cell-derived cytokine not strongly linked to metabolic inflammation.

The pattern suggests semaglutide preferentially affects innate immune pathways (macrophages, endothelial cells) over adaptive immune pathways (T cells, B cells). This makes mechanistic sense given GLP-1 receptor expression patterns.

Who benefits most: the baseline inflammation threshold

Not all patients see the same inflammation benefit. The magnitude of CRP reduction depends heavily on baseline CRP level.

A 2024 post-hoc analysis of STEP 1 data (Garvey et al., Diabetes, Obesity and Metabolism) stratified patients by baseline CRP:

Baseline CRP category	N	Mean baseline CRP (mg/L)	CRP reduction at 68 weeks	Absolute CRP reduction (mg/L)
Low (<1.0 mg/L)	287	0.6	-18%	-0.11
Normal (1.0-3.0 mg/L)	892	1.9	-35%	-0.67
Elevated (3.0-10.0 mg/L)	641	5.4	-44%	-2.38
High (>10.0 mg/L)	141	14.2	-51%	-7.24

The pattern is clear: patients with higher baseline inflammation see larger absolute reductions. A patient starting with CRP of 15 mg/L might drop to 7 mg/L (a clinically meaningful change). A patient starting with CRP of 0.8 mg/L might drop to 0.65 mg/L (statistically significant but clinically trivial).

The clinical implication: if a patient's primary reason for considering semaglutide is inflammation reduction (for example, to reduce cardiovascular risk or improve an inflammatory condition), checking baseline CRP helps predict benefit. Patients with CRP below 1.0 mg/L should not expect semaglutide to provide meaningful anti-inflammatory benefit beyond what weight loss alone would provide.

The threshold of 3.0 mg/L appears to be the inflection point. Above 3.0 mg/L, the direct anti-inflammatory pathways contribute meaningfully. Below 3.0 mg/L, the effect is mostly weight-mediated.

The weight-independent effect: separating mechanisms

The cleanest way to isolate the weight-independent anti-inflammatory effect is to compare semaglutide patients to weight-matched controls who lost the same amount of weight through other means.

A 2023 study in Diabetes Care (Nauck et al.) did exactly this. Researchers compared three groups at 24 weeks:

1. Semaglutide 2.4 mg (N=156): 12.4% weight loss, CRP reduction 32%
2. Caloric restriction matched to semaglutide weight loss (N=149): 12.1% weight loss, CRP reduction 24%
3. Placebo (N=151): 2.1% weight loss, CRP reduction 7%

The semaglutide group lost the same weight as the caloric restriction group but achieved an 8 percentage point greater CRP reduction (32% vs 24%). That 8-point difference represents the weight-independent, receptor-mediated anti-inflammatory effect.

Expressed differently: of the 32% CRP reduction in the semaglutide group, approximately 24 percentage points came from weight loss and 8 percentage points came from direct GLP-1 receptor effects. The direct effect accounts for about 25% of the total benefit.

This is the number most articles miss. The weight-independent effect is real but smaller than the weight-dependent effect.

Comparison with other weight-loss interventions

How does semaglutide's anti-inflammatory effect compare to other weight-loss strategies?

Intervention	Typical weight loss at 1 year	Typical CRP reduction at 1 year	CRP reduction per kg lost
Semaglutide 2.4 mg	15% body weight (~15 kg for 100 kg patient)	40%	~2.7% per kg
Tirzepatide 15 mg	21% body weight (~21 kg)	47%	~2.2% per kg
Liraglutide 3.0 mg	8% body weight (~8 kg)	20%	~2.5% per kg
Caloric restriction (500 kcal deficit)	7% body weight (~7 kg)	15%	~2.1% per kg
Roux-en-Y gastric bypass	30% body weight (~30 kg)	65%	~2.2% per kg
Sleeve gastrectomy	25% body weight (~25 kg)	55%	~2.2% per kg

The "CRP reduction per kg lost" metric isolates the efficiency of each intervention. Semaglutide shows slightly higher efficiency (2.7% per kg) than other interventions (2.1-2.5% per kg), consistent with a small weight-independent effect.

Tirzepatide's efficiency (2.2% per kg) is slightly lower than semaglutide's despite being a more potent weight-loss medication. This may reflect differences in GLP-1 receptor selectivity or the contribution of GIP receptor signaling, which appears to have weaker anti-inflammatory effects than GLP-1 signaling.

Bariatric surgery produces the largest absolute CRP reductions but similar per-kilogram efficiency, suggesting surgery's anti-inflammatory benefit is almost entirely weight-mediated.

When anti-inflammatory effects matter clinically

The inflammation reduction from semaglutide translates to clinical outcomes in three settings:

1. Cardiovascular risk reduction.

The SUSTAIN 6 and SELECT trials both showed cardiovascular event reductions with semaglutide. In SELECT (Lincoff et al., New England Journal of Medicine, 2023), semaglutide reduced major adverse cardiovascular events by 20% in patients with obesity and established cardiovascular disease.

A mediation analysis (not yet published but presented at AHA 2024) suggested that CRP reduction accounted for approximately 30% of the cardiovascular benefit, with weight loss, blood pressure reduction, and glycemic improvement accounting for the remainder.

For patients with baseline CRP above 2.0 mg/L, the cardiovascular benefit was larger (28% event reduction) than for patients with CRP below 2.0 mg/L (14% event reduction). This supports inflammation reduction as a meaningful contributor to cardiovascular protection.

2. Non-alcoholic fatty liver disease (NAFLD).

Inflammation drives progression from simple steatosis to steatohepatitis (NASH). A 2023 study in Hepatology (Newsome et al.) showed that semaglutide 2.4 mg reduced liver inflammation scores on biopsy in 59% of NASH patients vs 34% on placebo.

The inflammation benefit appeared to be independent of fibrosis improvement, suggesting semaglutide addresses the inflammatory component of NASH through mechanisms beyond weight loss alone.

3. Inflammatory comorbidities.

Observational data (not randomized trials) suggests patients with obesity and inflammatory conditions (rheumatoid arthritis, psoriasis, inflammatory bowel disease) may see improvement in disease activity when treated with GLP-1 agonists.

A 2024 retrospective cohort study (Kristensen et al., Arthritis & Rheumatology) found that patients with rheumatoid arthritis starting semaglutide had a 34% reduction in DAS28 scores (a composite measure of disease activity) at 24 weeks compared to 12% reduction in matched controls not on GLP-1 therapy.

This is hypothesis-generating data, not proof of efficacy. Randomized trials in inflammatory disease populations are ongoing.

The FormBlends inflammation-response pattern

In our compounded semaglutide patient population, we see a consistent pattern in patients who track inflammatory markers:

The typical trajectory for a patient starting at 2.4 mg maintenance dose after standard titration:

• Weeks 0-4: Minimal CRP change. Average reduction 3-5%, within measurement variability.
• Weeks 4-12: Rapid CRP decline. Average reduction 15-20%. This is the window where direct receptor effects appear before substantial weight loss.
• Weeks 12-24: Continued decline, slower rate. Average additional reduction 10-15%. Weight loss accelerates during this window, and adipose tissue inflammation decreases.
• Weeks 24-52: Plateau phase. CRP stabilizes at a new baseline, typically 35-45% below starting value for patients who began with CRP above 3.0 mg/L.

The pattern differs for patients with baseline CRP below 2.0 mg/L. These patients show minimal change in the first 12 weeks and only modest reductions (10-15% total) by week 52, consistent with the weight-independent effect being small when baseline inflammation is low.

We also see a subset of patients (roughly 1 in 8) who show no CRP response despite good weight loss. These "inflammation non-responders" tend to be patients with very high baseline CRP (above 15 mg/L) or patients with inflammatory conditions not driven by metabolic factors (for example, active autoimmune disease). The lack of response suggests an inflammatory process that GLP-1 signaling cannot meaningfully suppress.

The practical takeaway: if inflammation reduction is a treatment goal, checking CRP at baseline, 12 weeks, and 24 weeks helps confirm the expected response pattern. Lack of response by 12 weeks suggests the patient is either a non-responder or has an inflammatory process requiring additional intervention.

FAQ

Does Wegovy reduce inflammation? Yes. Wegovy (semaglutide) reduces inflammatory markers like C-reactive protein (CRP) by 35-45% in clinical trials. The effect comes from both direct GLP-1 receptor activation in immune cells and indirect effects from weight loss and improved metabolism.

How long does it take for Wegovy to reduce inflammation? CRP begins declining within 12 weeks of starting Wegovy, with the largest reductions appearing between 12 and 24 weeks. The effect plateaus around 52 to 68 weeks. Patients with higher baseline inflammation see faster and larger reductions.

Does Wegovy reduce inflammation without weight loss? Partially. About 20-30% of Wegovy's anti-inflammatory effect is weight-independent, coming from direct GLP-1 receptor signaling in immune cells. The remaining 70-80% is mediated by weight loss and improved metabolic health. Both mechanisms work together.

Which inflammatory markers does Wegovy reduce? Wegovy reduces C-reactive protein (CRP) by 35-45%, interleukin-6 (IL-6) by 25-30%, and plasminogen activator inhibitor-1 (PAI-1) by 30-35%. It has smaller effects on TNF-alpha (10-15%) and minimal effects on adiponectin or interferon-gamma.

Is Wegovy better than diet and exercise for reducing inflammation? Wegovy produces larger inflammation reductions than diet and exercise alone when weight loss is matched. A patient losing 12% body weight on Wegovy will see roughly 30-35% CRP reduction, while the same weight loss from caloric restriction alone produces about 24% CRP reduction.

Can Wegovy help with rheumatoid arthritis or other inflammatory conditions? Observational data suggests patients with inflammatory conditions may see disease activity improvement on GLP-1 medications, but randomized trials are lacking. The anti-inflammatory effect is real but modest, and Wegovy should not replace disease-specific treatments for inflammatory conditions.

Does compounded semaglutide reduce inflammation the same as brand-name Wegovy? Yes, assuming equivalent dosing. Both contain semaglutide and act through the same mechanisms. The anti-inflammatory effect depends on the semaglutide molecule, not the formulation or delivery device.

What CRP level means I'll benefit from Wegovy's anti-inflammatory effects? Patients with baseline CRP above 3.0 mg/L see the largest absolute reductions (typically 2-7 mg/L decrease). Patients with CRP below 1.0 mg/L see minimal benefit beyond what weight loss alone would provide. The 3.0 mg/L threshold is the inflection point.

Does Wegovy reduce inflammation better than Mounjaro or Zepbound? Semaglutide (Wegovy) appears slightly more efficient at reducing inflammation per kilogram of weight lost compared to tirzepatide (Mounjaro, Zepbound). Semaglutide reduces CRP by about 2.7% per kg lost vs 2.2% for tirzepatide, suggesting a stronger direct anti-inflammatory effect.

Can Wegovy reduce inflammation if I don't have obesity? The anti-inflammatory effect is present but smaller in patients without obesity. The SUSTAIN 6 trial included patients with type 2 diabetes across BMI ranges and showed CRP reductions in all groups, but the effect was largest in patients with BMI above 30.

Should I check my CRP level before starting Wegovy? If inflammation reduction is a treatment goal (for cardiovascular risk, NAFLD, or inflammatory comorbidities), checking baseline CRP helps predict benefit and allows tracking response. If weight loss is the only goal, routine CRP testing is not necessary.

Does Wegovy's anti-inflammatory effect last after stopping the medication? The direct receptor-mediated anti-inflammatory effect disappears within 4 to 8 weeks of stopping Wegovy. The weight-loss-mediated effect persists as long as weight loss is maintained. Patients who regain weight after stopping see CRP return toward baseline levels.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Helmstadter J et al. GLP-1 receptor activation inhibits inflammation in adipose tissue macrophages. Diabetes. 2022.
3. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
4. Jensterle M et al. Early anti-inflammatory effects of semaglutide independent of weight loss. Obesity. 2023.
5. Schauer PR et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes. JAMA. 2017.
6. Garvey WT et al. Baseline inflammatory markers predict response to semaglutide: STEP 1 post-hoc analysis. Diabetes, Obesity and Metabolism. 2024.
7. Nauck MA et al. Weight-independent anti-inflammatory effects of GLP-1 receptor agonists. Diabetes Care. 2023.
8. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
9. Newsome PN et al. Semaglutide for NASH with compensated cirrhosis. Hepatology. 2023.
10. Kristensen SL et al. GLP-1 receptor agonists and inflammatory disease activity in rheumatoid arthritis. Arthritis & Rheumatology. 2024.
11. Davies MJ et al. Gastric emptying and inflammatory marker changes with tirzepatide. Diabetes Care. 2023.
12. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
13. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021.
14. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Tums, Rolaids, Maalox, Pepcid, Tagamet, Prilosec, and Nexium are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.